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1. Introduction 
Neuropathic Pain is a term referred to “pain arising as a direct consequence of a lesion 
affecting the somatosensory system”. As a first line option, oral medications are mostly 
used, as they are easily available, relatively safe, and do not need much resources. They 
include antidepressants in the form of tricyclics, newer selective reuptake inhibitors of 
serotonin and norepinephrine, gabapentin, pregabalin etc. Although neuropathic pain 
conditions do share some common clinical features, they are quite diverse when considered 
individually according to their etiology and pathogenesis. Hence not all patients and not all 
types of neuropathic pain respond to such oral therapy. In practice patients are given a form 
of such neuropathic pain medication along with or without an opioid, depending upon the 
extent of pain that the patient suffers. Opioids are potent analgesics but are not a good 
choice for neuropathic pain conditions. With time the clinician is left with fewer alternatives 
and furthermore, with the the increasing knowledge that escalation of opioid therapy will 
perhaps lead to hyperalgesia and tolerance, it becomes necessary to explore other options. 
Among the other options one can always consider to explore treatment with intravenous 
medication such as Ketamine, Lidocaine, and Magnesium etc. This chapter would highlight 
the use of ketamine and lidocaine in the form of drug profile, the pharmacological basis 
behind its use, strategies to use, important side effects and limitations and available 
evidence base, including a review of randomised controlled studies. Both are considered 
separately in two different parts. References for both the parts are given at the end, in 
separate sections. 
Part A: Ketamine 
1. Ketamine is a potent anesthetic and analgesic compound with unique actions. It is a 
phencyclidine (PCP), anesthetic compound with its chemical name being 2-O-chlorophenyl-
2-methylamino- cyclohexanone. It contains an asymmetric carbon atom and exists as 2 
isomers {(R) and (S)}, of which the (S) isomer is the more potent general anesthetic and 
NMDA antagonist. Commercially available ketamine formulations are a racemic mixture of 
S (+) and R (-) preserved in benzethonium chloride (Orser, 1997; Ben Ari, 2007). Animal 
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studies has shown that the affinity at the phencyclidine binding site of S (+) ketamine at the 
NMDA receptor is four fold that of R(-). Studies in rats and mice have demonstrated that the 
S (+) form is five times more hypnotic and three times more analgesic than the R (-) raceme 
(White, 1985). The incidence of side effects is although similar, overall it is theoretically less, 
as you need less S ketamine for a therapeutic action and the side effects are observed to be 
proportional to their blood levels. 
Ketamine is unique because no other drug combines the property of anesthetic, analgesic 
and amnesic properties. The search for a PCP compound with less hallucinogenic side 
effects led to ketamine (CI-581), first synthezised in 1962 by Calvin Stevens at Parke-Davis 
and Co, and introduced into clinical practice during 1970 after investigation from Corssen 
and Domino in 1964 on human volunteers (Sinner & Graf, Sabia, 2011). Apart from the 
property of dissociative anesthesia, its analgesic effects have been widely investigated, in 
both experimental and human studies. The analgesic properties of ketamine primarily exist 
because of its property to block NMDA receptor in a non-competitive fashion. Other 
clinically known NMDA-receptor blockers include dextromethorphan, dextrorphan, 
memantine, and amantadine. There are other mechanisms of analgesia which could be 
partly responsible for the actions of ketamine. Ketamine is also active at opioid, 
norepinephrine, serotonin, and muscarinic cholinergic receptors; it acts by inhibiting 
serotonin and dopamine reuptake and inhibits voltage-gated Na+ and K+ channels (Okon, 
2007). Indeed, some studies suggest that analgesic effects of Ketamine are actually due to its 
activation of monoaminergic descending inhibitory pathways, rather than NMDA receptor 
(Okon, 2007). To understand its mechanism one has to also understand the role of NMDA 
receptors, at least briefly, as related to pain mechanisms.  
2. NMDA receptor, central sensitization and chronic pain 
1. NMDA receptors are known to be involved in the development of wind up 
phenomenon and generation of central sensitization and hence chronic pain. 
2. There is increasing evidence that NMDA receptors are also involved in peripheral 
sensitization and visceral pain. 
3. Evidence shows that Ketamine primarily acts at NMDA receptors but also has actions at 
other sites. 
2.1 Pain is mediated through C (unmyelinated) and A-delta (thinly myelinated) fibres 
The primary excitatory neurotransmitter released via C fibres is Glutamate. This is the major 
excitatory neurotransmitter in the mammalian nervous system and modulates several 
functions through subtypes of glutaminergic receptor: the N-methyl-D-aspartate (NMDA) 
subtype, the kainite, the AMPA (l-amino-3-hydroxy-5-methylsoxasole-propionic acid) 
subtype, and the metabotropic subtype (Bennett, 2000). NMDA receptor is also called 
“coincidence detector”, as several events must combine to activate it. Apart from glutamate, 
glycine is also needed as a co-agonist (Carpenter, 1999). NMDARs display a number of 
unique properties that distinguish them from other ligand-gated ion channels. First, the 
receptor controls a cation channel that is highly permeable to monovalent ions and calcium. 
Second, simultaneous binding of glutamate and glycine, the co-agonist, is required for 
efficient activation of NMDAR. Third, at resting membrane potential the NMDAR channels 
are blocked by extracellular magnesium and open only on simultaneous depolarization and 
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agonist binding, thus both depolarization of the postsynaptic neuron and presynaptic 
release of glutamate and glycine are required for maximum current flow through the 
NMDAR channel. The response of ionotropic glutamate receptors to agonists is usually 
potentiated after phosphorylation. 
Wind-up is a progressive, frequency-dependent facilitation or increase in the magnitude of 
C-fiber evoked responses, of the responses of a neurone observed on the application of 
repetitive (usually electrical) stimuli of constant intensity. Central sensitization refers to 
enhanced excitability of dorsal horn neurons and is characterized by increased spontaneous 
activity, decrease in response threshold, enlarged receptive field (RF) areas, and an increase 
in responses evoked by large and small caliber primary afferent fibers (Jun Li, 1999; Cook, 
1987). Sensitization of dorsal horn neurons often occurs following tissue injury and 
inflammation and is believed to contribute to hyperalgesia. 
2.2 NMDA activation  
Because it is a transmembrane protein, it spans the electric field generated by the membrane 
potential. The magnesium binding site within the receptor is physically located within this 
electric field. As the cell is depolarized, the negative field effect weakens and in this phase, 
when the magnesium is absent, Ca2+, Na+ and K+ -ions flow through the channel. 
Magnesium ions are rapidly substituted by next set of magnesium ions during 
repolarization. The Ca2+ influx is crucial for the induction of the NMDA receptor-dependent 
long-term potentiation (LTP), which is thought to underlie neuronal plasticity, including 
development of central sensitization, learning and memory. The activation of the NMDA 
receptor leads to a Ca2+ /calmodulin-mediated activation of NO synthetase, which plays a 
crucial role in nociception and neurotoxicity. The primary endogenous neurotransmitter 
active at NMDA-R is glutamate, the main EAA. It is likely that glutamate facilitates the 
activation of NMDAR, by causing the intracellular elevation of calcium, leading to a cascade 
of excitatory events. The sequence of these intracellular signaling events is complex. 
However, they seem to result in the activation of protein kinase C and elevation of levels of 
nitrous oxide, which in turn, leads to enhanced release of other EAAs (Sinner & Graf, 2008; 
Petrenko, 2003; Zhou, 2011).  
2.3 Peripheral NMDA receptors and their involvement 
Several studies have demonstrated the presence of peripheral NMDA receptors which are 
involved with pain. Local injections of glutamate or NMDA agonists result in nociceptive 
behaviors that can be decreased by peripheral administration of NMDAR antagonists 
(Zhou, 1996). Pederson found that ketamine infiltration had only brief local analgesic effects, 
but several measures of pain and hyperalgesia were unaffected. Therefore, a clinically 
relevant effect of peripheral ketamine in acute pain seems unlikely. The local anesthetic 
action of ketamine can also result from its blocking of cations, and it has been demonstrated 
that it enhances the local anesthetic and analgesic actions of bupivacaine used for infiltration 
anesthesia in a postoperative setting (Tverskoy, 1996) and also the development of primary 
and secondary hyperalgesia after an experimental burn injury (Warnke, 1997). Topical 
application of ketamine ointment has been recently reported to reduce pain intensity and to 
attenuate allodynia in patients with an acute early dystrophic stage of complex regional pain 
syndrome type I (Ushida, 2002). 
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Fig. 1. NMDA Receptor and Mediators involved 
3. Pharmacokinetics and pharmacodynamics 
The bioavailability after IV administration is about 90%, whereas bioavailability after oral 
and rectum administrations is 16%, indicating significant first-pass effect by the liver. 
Particularly, oral administration of ketamine is accompanied by extensive first-pass 
metabolism, and the plasma levels of (R and S)-norketamine are about three times higher 
than the levels produced by IV or IM administration (Yanagihara 2003). Nor Ketamine, 
which is excreted in urine, is thought to have about 30% of the analgesic potency of the 
parent drug (Sinner & Graf, 2008). Ketamine is soluble in both water and lipids. Because of 
its high lipid solubility, it crosses the blood–brain barrier rapidly leading to the onset of 
action within 1-3 minutes and is rapidly redistributed (Sabia, 2011). Brain to plasma ratio for 
ketamine is estimated to be 6.5:1, suggesting ketamine’s preferential accumulation in the 
brain (Orser, 1997). Timing to maximum pain relief remains a controversial issue, since it 
depends on the mechanism of the pain. In the Mercadante et al series (Mercandate, 2010), 
maximum pain relief after a single intravenous dose occurred between 30 and 60 minutes 
after the infusion. Elimination due to metabolism has a half-life of 2 to 3 h. The plasma 
clearance is 15–20 ml/kg per minute in adults and higher for S (+)-ketamine than for the 
enantiomer. It has a large volume of distribution in the steady state (Vss: 3.1 L/kg), owing to 
its low plasma-protein binding of 27%. Because of the large Vss and relatively rapid 
clearance, it is clinically possible to administer ketamine as an infusion at 25 to 100 μg/min 
(Sabia, 2011). With scheduled administration, a steady state is achieved in 12-15 hours. The 
initial metabolite is norketamine and is produced by the N-demethylation of ketamine, 
which is mediated by the hepatic cytochrome P450 enzymes (Goldberg, 2010). This is shown 
to be enantioselective, with the N-demethylation of (S)-ketamine proceeding faster than that 
of (R)-ketamine (Kharasch, 1992). A dose reduction in patients with hepatic impairment is 
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advised due to the prolonged duration of action. In renal failure, dose increases may be 
considered. The urinary excretion of unmetabolized drug is approximately 4%. In forensic 
medicine, ketamine use can be detected in the urine for about 3 days. Concentration ranges 
for ketamine in urine have been reported as low as 10 ng/ml and up to 25 μg/ml.  
 
Chemical Name 2O-chlorophenyl-2-methylamino-cyclohexanone 
Chemical Structure C 13 H 16 ClNO 
Molecular Weight 274.4 M 
Melting Point 258°C and 261°C 
Solubility Both lipid and water soluble 
Isomers 
S(+) and R(-) isomers 
S 3-4 times more potent than R as an anesthetic 
BIOAVAILABILITY 
Intramuscular 93% 
Nasal 25%-50% 
Oral 17% 
Protein Binding 20%–30% 
ONSET OF EFFECTS 
Intravenous seconds 
Intramuscular 1-5 mins 
Nasal 5-10 mins 
Oral 15-20 mins 
HALF LIFE 
Alpha Alpha half-life (2–4 min) 
Beta Beta half-life  8–16 min (redistribution) 
Terminal/elimination 2.5 to 3 hrs 
Table 1. Pharmacological Properties 
 
Fig. 2. Chemical Structure of Ketamine 
The observation that oral administration is associated with higher serum concentrations 
of the main metabolite of ketamine, norketamine, compared to other routes of 
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administration has led to the idea that norketamine contributes to the analgesic effects of 
ketamine (Fischer, 2010). The oral bioavailability of ketamine after a single oral dose is 
about one fifth of the availability after an intravenous injection. When ketamine is 
administered as a racemic mixture, both S-norketamine and R-norketamine is formed. 
Analgesic effects of ketamine were observed with plasma levels of 100–200 ng/ml (sum of 
S- and R-isomer) following intramuscular and intravenous administration. Effective 
analgesia following oral dose occurs at much lower concentrations of ketamine (40 ng/ml) 
(Grant et al., 1981). Clinical studies have shown that with a prolonged infusion of 
ketamine the ratio of ketamine to norketamine serum levels remains constant at 3:14 
(Ebert, 1997). It is also not sure why some patients do not respond to ketamine and in 
particular to oral ketamine. Rabben and Oye found a positive correlation between a long 
pain history and lack of analgesic effect and also between a short pain history and a long-
term analgesic effect of low-dose ketamine. This finding was also observed in the study of 
Mathiesen et al, where patients suffering from pain for more than 5 years did not observe 
any analgesic effects. These results indicate that pain mechanisms are subject to 
alterations with time and that these alterations involve transition from NMDA to non-
NMDA receptor-mediated transmission in central pain pathways.   
4. Mechanisms of action of ketamine  
4.1 Ketamine blocks the NMDA channel by 2 distinct mechanisms 
1) it blocks the open channel and there by reduces channel mean open time, and 2) it decreases 
the frequency of channel opening by an allosteric mechanism (Orser, 1997). But the precise 
interactions of ketamine with NMDARs are still being elucidated (Orser, 1997; Kohrs, 1998). 
The main interaction is supposed to result from its binding to the phencyclidine receptor in the 
NMDA channel and thus inhibiting the glutamate activation of the channel in a non-
competitive manner (Kohrs, 1998). However the complete spectrum of effects on NMDARs is 
not completely clear. There may be some actions mediated differently, which are selectively 
active at low doses. Drugs like memantine and amantadine have no appreciable anesthetic or 
analgesic properties but still inhibit NMDARs.  This dual mechanism may be clinically 
relevant in treating patients with low dose and high dose ketamine, and my may in fact act 
through different pathways apart from molecular mechanisms.  
4.2 Other mechanisms of possible ketamine actions 
1. Opioid: It is said to be an antagonist at mu and agonist at kappa receptors (Sinner & 
Graf, 2008; White, 1982). 
2. Ketamine is known to produce local anesthetic effect similar to lidocaine and 
bupivacaine. Spinal administration of ketamine mixed with epinephrine produces 
motor and sensory block without respiratory depression or hypotension, even in 
humans, but are associated with central effects unlike in dogs. This has been used in 
war casualties. 
3. Activation or increase in the activity of descending monoaminergic system 
(serotonergic). 
4. Effects on muscarinic cholinergic receptors are not shown to be responsible for 
analgesia. 
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5. A practical algorithm for ketamine in chronic pain 
For long term use  
1. Monitor for Ketamine induced changes in cognition, memory and mood disturbances. 
2. Monitor for Ketamine addiction, using the same guidelines as opioids. 
3. Long term neuraxial use is not advised as it is supposed to be associated with side 
effects. 
 
6. An analysis of RCT’s of parenteral ketamine 
The evidence for the use of Ketamine in chronic, neuropathic pain consists of RCT’s, case 
reports, case series, retrospective studies and experimental studies. RCT’s are considered as 
“level 2 evidence”, as per the EBM standards. We performed a search of Pubmed and 
EMBASE to look for RCT’s using ketamine for chronic pain. We also included studies on 
cancer pain management. Limits were put on English language and human controlled trials. 
Mesh terms used were as following: ‘ketamine’, ‘administration’, ’chronic pain’, 
’neuropathic pain’, ’cancer pain’, ‘intravenous’, ‘subcutaneous’, ‘intramuscular’. Articles 
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describing a study based on animal research and research about acute postoperative pain 
and reviews were excluded by entering the term ‘NOT’ in the search strategy. Only abstracts 
were not included. We also cross referenced our search results with previous review articles 
(Hocking, 2003; Bell 2009). Finally a total of 33 articles were selected. Out of them 3 articles 
were excluded:  Eide (1997): this is an N=1 trial, Hagelberg (2010): this trial was just looking 
at how antibiotic levels affect ketamine levels (the identical dose of ketamine was used in 
both arms of the trial), Neisters (2011): experimental study on human volunteers. Most 
included small numbers of patients with a variety of study objectives, designs and outcome 
measurements. None of the included studies had a high quality methodological design. Due 
to the above reasons and with the heterogeneity of data, it was not possible to perform a 
quantitative analysis. 
In total we obtained 30 studies. Categorisation according to clinical diagnosis showed; 3 
studies of CRPS, 2 were on fibromyalgia, 2 on ischemic pain, 2 on post herpetic neuralgia, 3 
on peripheral neuropathic pain, 1 on post traumatic pain, 3 studies on various chronic 
neuropathic pain conditions, 2 on post nerve injury pain, 2 on phantom limb pain, 2 on 
whiplash, 1 on odontolgia and TMJ pain, 3 on spinal cord injury pain, 1 on post stroke pain, 
1 on migraine treatment and prophylaxis, 1 on cancer pain, 1 was an experimental study. 
According to route of administration there were: 1 study on subcutaneous infusion, 2 
studies on intranasal use, 1 study on intramuscular use, and a total of 26 studies on 
intravenous use.   
 
Author/ 
Year 
Design 
Patient 
population 
and numbers
Design/ 
Methodology
Outcomes 
Withdrawal/Side 
Effects 
Carr 
(2004) 
DB RCT 
PLC 
N=22; 
Chronic pain; 
currently on 
24hr opioid 
regimens 
Ketamine 
intranasal 
spray 
(Ketamine HCL 
10%)  vs. 
placebo (NS) 1-
5 sprays q90s x 
5 for 
breakthrough 
pain (BTP) 
Significantly lower 
BTP after IN 
Ketamine vs. 
placebo; pain relief 
up to 60 min. No 
patient in 
treatment arm 
required usual 
breakthrough pain 
meds vs. 7 who did 
in treatment arm 
4 patients 
reported a change 
in taste, 2 
experienced 
increase in blood 
pressure, 1 
reported nasal 
passage irritation 
and rhinorrhea  
Huge 
(2010) 
DB RCT 
N=16; 
Chronic 
neuropathic 
syndromes 
Ketamine 
0.2mg/kg 
intranasal vs. 
Ketamine 
0.4mg/kg 
intranasal five 
sprays each 
nostril x 1 
Significant 
decrease in resting 
pain in both 
groups up to 1 hr 
after application on 
100 point pain 
scale; no change in 
quantitative 
sensory testing 
75% of subjects 
reported vertigo, 
70% reported 
sedation; 60% 
reported 
difficulty 
concentrating 
Table 2. RCT’s of Intranasal Route 
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6.1 Intranasal route 
This route was used in 2 studies, breakthrough pain and various neuropathic pain 
conditions. This is also utilised in some outpatient clinics to help identify patient’s 
responsiveness to ketamine without involving the logistics and preparation as necessary for 
IV ketamine infusion. Both studies were positive with respect to ketamine’s analgesic 
actions. Huge studies the use of intranasal S ketamine randomised into 2 different doses (0.2 
mg/kg and 0.4 mg/kg). Plasma concentrations of S Ketamine and S norketamine were also 
studied. The analgesic effects co-related with maximum plasma range of metabolites for 
both doses after which it decreased.  
Intranasal ketamine can act similar to a parenteral route as it can bypass the hepatic 
metabolism. Apart from the known side effects, intranasal use can cause transient change in 
taste, rhinorrhea, irritation of nasal passage (Carr, 2004).  
6.2 Intramuscular route 
IM use is considered parenteral and for all reasons it is considered similar to IV ketamine 
administration, except that the onset of effect can be prolonged. The only study was done on 
TMJ pain patients suspected of myofascial pain. Ketamine injection was given as a single 
dose injection into the most painful part of masseter at a dose of 0.2 ml, in comparison to 
placebo. There were no differences in pain scores except a minor effect on jaw opening. 
Although the reason for injection at the local painful site is not provided, it may be assumed 
that a local or peripheral site of action was considered. 
 
Author/ 
Year 
Design
Patient 
population 
and numbers
Design/ 
Methodology 
Outcomes 
Withdrawal/ 
Side Effects 
Castrillon 
(2008) 
DB RCT
N=14; 
Myofascial 
TMJ syndrome
Ketamine injection 
(0.2 ml) into 
masseter vs NS 
injection x1 
No difference in 
VAS pain 
questionnaire 
scores 
None 
Table 3. RCTs of Intramuscular Route 
6.3 Subcutaneous route 
The subcutaneous route is also considered parenteral. Although there have been many case 
reports and case series using sc route, there was only one RCT. Nicolodi et al used sc  
 
Author/ 
Year 
Design
Patient 
population 
and numbers
Design/ 
Methodology 
Outcomes 
Withdrawal/ 
Side Effects 
Nicolodi 
(1995) 
DB RCT 
PLC 
N=17;  
Chronic 
migraine 
headaches 
Ketamine (80 
mcg/kg) subcut 
vs Placebo (NS) 
subcut daily x 3 
weeks 
Significant 
decrease in 
frequency and 
severity of 
migraine attacks 
"Most" patients 
experienced 
mild side effects 
Table 4. RCTs of Subcutaneous Route 
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ketamine as bolus and 3 times daily for acute migraine and its prophylaxis, compared to 
placebo infusion. Ketamine gave marked pain relief in both acute situation and as a 
prophylactic. However, subcutaneous administration of ketamine is associated with 
significant side effects. Apart from the central side effects such as hallucinations and 
delirium, peripheral side effects at the injection site are common. Ketamine is an irritant and 
requires daily changing of injection site (Hocking, 2003). Itching and painful indurations at 
the injection site were also observed by Eide et al (1995). Heparin ointment is supposed to 
help with this troublesome side effect (Klepstad, 1997) 
6.4 Intravenous administration of Ketamine 
Out of 26 studies of IV ketamine, 1 was experimental. Oga demonstrated that pain reduction 
with ketamine is correlated with ketamine induced changes in hallucinatory behaviour and 
excitement as measured by brief psychiatric rating scale (BPRS).   
6.4.1 Whiplash disorder  
Ketamine was found to be beneficial in both the studies. Both were done by Lemming et al. 
The exact nature of pathology in whiplash is still unknown. Interventional treatments such 
cervical facet denervation has been found to be very effective in many patients. The utility of 
ketamine in this group of patients needs further studies with well defined inclusion criteria. 
6.4.2 Pain of vascular origin 
Two studies (Mitchell, 2002; Perrson, 1998) examined the effect of ketamine on critical limb 
ischemia and arteriosclerosis obliterans respectively. Both had positive results. The numbers 
treated were small (total N=16). Ketamine at a dose of 0.45 mg/kg fared better than 
Morphine 10 mg in arteriosclerosis patients. 
6.4.3 Fibromyalgia 
This is perhaps the least understood of neuropathic pain conditions despite being quite 
prevalent. Although the etiology is unknown the pathology does involve myofascial and 
connective tissue layers, at least in terms of its involvement. Ketamine was used for 
fibromyalgia in 2 studies, both showing positive results.  
6.4.4 Post amputation/phantom limb pain 
This condition is quite resistant to treatment and up to 80% of patients, post amputation, 
develop phantom pain sometime during their life time. Central sensitization and wind-up 
phenomenon have been well demonstrated in these conditions. There is reorganisation of 
cortical representation as well, which is perhaps secondary to the above changes. Ketamine 
or other NMDA antagonists have a definite role, at least as understood through their 
pharmacological effects. There have been only 2 studies (Eichenberger, 2008; Nikolajsen, 
1996) examining the role of ketamine IV infusions in this condition. Both found positive 
results with ketamine treatment. Unfortunately the duration of treatment effect has not been 
clearly followed. Perhaps this condition deserves more studies to establish the role of 
ketamine in its management.  
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6.4.5 Nerve injury pain and post herpetic neuralgia 
These two are considered together as they both involve destruction of nerve elements, and 
cause deafferentation pain. Altogether there were 4 studies. Gottrup et al (2006) and Jorum 
et al (2003), both observed a decrease in spontaneous pain and not much effect on allodynia. 
However, Leung et al (2001) did not find any reduction in spontaneous pain but found 
decrease in stroking pain score. Eide et al (1994) found a decrease in over all pain score and 
found no difference in specific pain modalities. 
Felsby (1996) used ketamine in peripheral neuropathic pain and found that to significantly 
benefit spontaneous pain and also touch evoked allodynia.  
6.4.6 CRPS 
3 studies examined the role of ketamine in CRPS. All 3 found positive results. Sigtermans 
et al (2009) and Dahan et al (2011), both had 60 patients and employed increasing doses 
of ketamine titrated to best effect. The former study showed statistically significant 
difference in pain scores between placebo and ketamine, which lasted up to 11 weeks. 
The latter study employed the same protocol; however the study parameters were 
different. They performed a pharmacokinetic-pharmacodynamic modeling to study the 
effect. It demonstrated that the treatment effect/analgesia outlasts the actual treatment 
period (determined by serum levels) by 50 days. Schwartzman et al (2009) performed an 
outpatient based ketamine treatment study. Although it planned to include 20 patients in 
each arm, it was stopped after a total of 19 patients, as the interim analysis showed little 
placebo effect. CRPS patients showed statistically significant decrease in pain scores over 
many parameters such as pain the most affected area, burning pain, pain when touched 
gently, and over all pain score. Follow up to 3 months showed that some treatment 
effects lasted up to 5-8 weeks (pain when touched). Further they state that the dose 
employed in that study, 25mg/h (100mg/4h) is perhaps less effective considering their 
newer treatment protocol using 50mg/h showing much better results. Further studies on 
larger group of well selected patients are needed to establish the role of ketamine in 
CRPS. 
6.4.7 Central pain and spinal cord injury pain 
These neuropathic pain conditions are very challenging to treat as they are not localised and 
involve most parts of the body. The nature of pathology causing pain in these conditions is 
not clearly known. NMDARs are supposed to play a role. Three studies examined the role of 
ketamine with spinal cord injury patients. Amr et al (2010) used ketamine with gabapentin 
and found it to be more effective than gabapentin alone in study of 40 patients. The 
treatment effect was lost after 3-4 weeks. Kvanstrom et al (2003) used ketamine in a study of 
10 patients, with pain below the level of spinal cord injury. Ketamine reduced pain scores 
>50% in all 5 patients. It is not documented whether there was any longer duration effect. 
Eide et al (1995) examined 9 patients in a randomised protocol with cross over design. He 
compared ketamine with alfentanil and a placebo. It was found that both continuous and 
evoked pains were markedly reduced by the blockade of NMDA receptors by ketamine as 
well as by the activation of mu-opioid receptors by alfentanil.  
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Author/ 
Year 
Design
Patient 
population 
and 
numbers 
Design/ 
Methodology 
Outcomes 
Withdrawal/ 
Side Effects 
Amr (2010) 
DB 
RCT 
PLC 
N=40; 
Neuropathic 
pain 
secondary 
to spinal 
cord injury
Ketamine (80 mg IV 
infusion in 500 ml 
NS over 5 hours) 
plus 300 mg 
gabapentin TID vs 
placebo (NS) and 
300 mg gabapentin 
TID, daily X 1 week
Each day of 
infusion and weeks 
1 and 2 post-
infusion treatment 
arm had lower 
VAS scores that 
control arm; effect 
lost at post-
infusion weeks 3 
and 4 
3 patients with 
short acting 
delusions after 
infusion, 2 
patients with 
15% increase in 
heart rate 
during infusion 
Sitgermans 
(2009) 
SB 
RCT 
PLC 
N=60; 
CRPS-1 
Ketamine (1.2 
mcg/kg/min IV, 
increased as 
tolerated until good 
pain control up to 
maximum of 7.2 
mcg/kg/min IV) vs 
Placebo (NS) for 
100h 
Statistically 
significant  
decrease in 10 
point pain scale 
scores up to 12 
weeks after 
initiation of study; 
no difference in 
functional 
improvement 
63% of patients 
experienced 
nausea, 47% 
vomiting, 93% 
psychomimetic 
effects 
Lemming 
(2007) 
DB 
RCT 
PLC 
N=20; >1 
year of 
whiplash 
associated 
pain 
Ketamine (IV 
infused over 20 min 
to a plasma 
concentration of 
100 ng/ml) vs 
remifentanil (IV 
infused over 30 min 
to a plasma 
concentration of 
 1 ng/ml) vs 
combination vs 
placebo (NS) x 4 
sessions 
Both remifentanil 
and ketamine 
decreased habitual 
pain by VAS (no 
significant 
difference); 
ketamine had 
additional effect on 
electrical 
stimulation pain 
threshold 
15 ketamine 
only patients 
experienced 
some level of 
sedation, 2 had 
strange dreams, 
1 hallucinations, 
1 nausea 
Lemming 
(2005) 
DB 
RCT 
PLC 
N=33;Whipl
ash disorder
Ketamine (0.3 
mg/kg IV infused 
over 30 min) vs 
Lidocaine (5mg/kg 
IV) vs morphine 
(0.3mg/kg IV)  vs 
placebo (NS) x 1 
No significant 
difference in 
response between 
all treatment 
 arms; all treatment 
arms did illicit 
partial response 
Not 
Documented 
www.intechopen.com
Intravenous Therapies in the Management of Neuropathic Pain:  
A Review on the Use of Ketamine and Lidocaine in Chronic Pain Management 53 
Author/ 
Year 
Design
Patient 
population 
and 
numbers 
Design/ 
Methodology 
Outcomes 
Withdrawal/ 
Side Effects 
Persson 
(1998) 
DB 
RCT 
N=8; Lower 
extremity 
rest pain 
from 
arterioscle-
rosis 
obliterans 
Ketamine (0.15, 0.3, 
0.45 mg/kg IV over 
2 hr) vs morphine 
(10 mg IV) x 4 
sessions 
Dose dependant 
improvement in 
resting pain; 
complete 
resolution of pain 
at highest doses 
Dose 
dependent 
impairment in 
cognition and 
perception 
Yamamoto 
(1997) 
SB 
RCT 
PLC 
N=39; 
Central 
post-stroke 
pain with 
thalamic or 
supratha-
lamic 
regions 
Ketamine (5mg IV 
q5min x5) vs 
Morphine (3mg IV 
q5min x 6) vs 
Thiamylal (50mcg 
IV q5min x 5) vs 
Placebo (5 ml NS 
q5min x2) 
47.8% of patients 
had significant 
drop in VAS 
spontaneous pain 
scores; no comment 
on significance as 
compared to other 
groups 
2 patients had 
transient 
hallucinations 
and anxiety 
Felsby 
(1996) 
DB 
RCT 
PLC 
N=10; 
Neuropathic 
pain 
disorders 
Ketamine (0.2 
mg/kg loading dose 
followed by 0.3 
mg/kg/min 
infusion for one 
hour) vs 
Magnesium 
Chloride 
(0.16mmol/kg) vs 
placebo (NS) 
Significant 
reduction in pain 
and of area of 
allodynia by VAS; 
no change to 
detection and pain 
thresholds to 
mechanical and 
thermal stimuli 
7 patients 
reported 
anxiety or 
mood 
symptoms; 2 
patients became 
sedated 
Max (1995) 
DB 
RCT 
PLC 
N=8; 
Chronic 
post-
traumatic 
pain and 
global 
allodynia 
Ketamine (0.75 
mg/kg/hr IV; 
doubled at 60 and 
90 min if no effect, 
halved if side 
effects) vs Alfentanil 
(mean dose 11mg 
IV) vs placebo (NS) 
over 2 hours x 1 
Ketamine superior 
to Alfentanil for 
peak effect of pain 
relief and relief of 
allodynia by VAS 
pain scores 
3 patients 
sedated, 2 
muteness, 2 
dissociative 
reaction; 2 
nausea 
Backonja 
(1994) 
DB 
RCT 
PLC 
N=6; 
Neuropathic 
pain 
Premedicated with 
benzodiazapine 
then ketamine (250 
mcg/kg IV slow 
push) vs placebo 
(NS) 
3/6 patients had at 
least 50% reduction 
in pain, 4/6 had 
similar reduction in 
allodynia and 
hyperalgesia 
5 patients had 
side effects to 
ketamine 
(diplopia, 
nystagmus, 
psychomimetic 
effects, 
increased BP 
and HR) 
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Author/ 
Year 
Design
Patient 
population 
and 
numbers 
Design/ 
Methodology 
Outcomes 
Withdrawal/ 
Side Effects 
Kvarnstron 
(2004) 
10 PT 
DB 
RCT 
PLC 
Spinal Cord 
Injury with 
Pain Below 
Injury Level
Ketamine (0.4 
mg/kg IV) vs 
Lidocaine (2.5 
mg/kg IV) vs 
Placebo (NS) 
5 patients in 
ketamine group 
had >50% 
reduction in 
spontaneous VAS 
score 2 hours after 
administration 
7 patients 
reported 
dizziness, 
changes in 
vision or 
somnolence, 
 5 reported 
paresthesias 
Kvarnstrom 
(2003) 
DB 
RCT 
PLC 
N=12; Long 
lasting, 
post-
traumatic 
neuropathic 
pain 
Ketamine (0.4 
mg/kg IV) vs 
Lidocaine (2.5 
mg/kg) vs placebo 
(NS) infused over 40 
minutes 
Significant 
improvement in 
VAS scores with 
ketamine (mean 
decrease 55%) 
compared with 
placebo; no change 
in scores of thermal 
or mechanical 
stimulation 
100% of 
subjects 
reported 
somnolescence, 
75% light-
headed, 83% 
paresthesias, 
67% out of 
body sensation, 
50% changes in 
vision 
Baad-
Hansen 
(2007) 
Case-
Contro
l PRO 
DB 
PLC 
N=20; 10 
Patients 
with 
atypical 
odontalgia; 
10 healthy 
age/sex 
matched 
controls 
Ketamine (50 
mcg/kg then 
70mcg/kg IV) vs 
Fentanyl 
(1.43mcg/kg IV) vs 
Placebo (NS) 
No change in VAS 
pain score of 
ongoing AO pain 
5 patients 
reported 
dizziness, 4 
"feeling drunk", 
2 nausea 
Eide (1994) 
DB 
RCT 
PLC 
N=8; Post-
herpetic 
neuralgia 
Ketamine 
(0.15mg/kg IV) vs 
morphine vs 
placebo (NS) 
Overall "decrease 
in pain sensation" 
and decrease in 
wind-up pain with 
ketamine. No 
significant  
change in warm, 
cold, heat or tactile 
sensation. Both 
morphine and 
ketamine improve 
allodynia 
compared to 
placebo; 
"Side effects" 
seen in all 8 
ketamine 
patients 
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Author/ 
Year 
Design
Patient 
population 
and 
numbers 
Design/ 
Methodology 
Outcomes 
Withdrawal/ 
Side Effects 
Eide (1995) 
DB 
RCT 
PLC 
N=9; Post 
spinal cord 
injury 
dysethesia
Ketamine (60 
mcg/kg bolus then 
6 mcg/kg/min) vs 
alfentanil vs placebo 
(NS) 
Continuous and 
provoked pain 
were reduced with 
ketamine and 
alfentanil; no 
change in 
temperature 
sensation
"Bothersome 
dizziness" in 
one patient 
Eichenberg
er et al 
(2008) 
DB 
PLC 
RCT 
N=20; 
Phantom 
limb pain in 
any 
extremity 
from 
surgical or 
traumatic 
amputation
Ketamine (0.4 
mg/kg IV over 1 
hour with calcitonin 
200 IE  x 4 total 
treatments every 
other day) vs 
Calcitonin vs 
placebo vs 
Ketamine (0.4 
mg/kg IV over 1 
hour) - later 
additions to study 
design 
Statistically 
significant 
reduction in VAS 
scores only in 
ketamine group 
(not combination). 
60% of treatment 
arm had at least a 
50% reduction in 
symptoms 
5 patients 
became 
unconscious, 
experienced 
visual 
hallucination, 
and hearing 
impairment  
during ketamine 
administration; 
in combination 
therapy, 4 
patients became 
nauseous, had 
visual 
hallucinations; 9 
became dizzy 
and 1 became 
unconscious 
Nikolajsen 
(1996) 
DB 
RCT 
PLC 
N=11; Post-
amputation 
stump pain
Ketamine (0.1 
mg/kg IV bolus 
then 7 mcg/kg/min 
over 45 minutes) vs 
placebo (NS) 
Improvement of 
McGill Pain 
Questionnaire and 
VAS pain Scores in 
treatment arm; 
decreased 
incidence of wind-
up pain.
6 patients 
reported 
sensation of 
"insobriety"; 3 
reported" 
discomfort" 
Sorensen 
(1997) 
DB 
RCT 
PLC 
N=18; 
Fibromyalgia
Ketamine 
(0.3mg/kg IV) vs 
Morphine 
(0.3mg/kg IV) vs 
Lidocaine (5mg/kg 
IV)  vs Placebo (NS) 
x 1 dose 
All treatment arms 
showed significant 
reduction of resting 
pain; no comment 
on superiority/ 
inferiority of 
ketamine to other 
treatments
Not 
Documented 
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Author/ 
Year 
Design
Patient 
population 
and 
numbers 
Design/ 
Methodology 
Outcomes 
Withdrawal/ 
Side Effects 
Graven-
Nielsen 
(2000) 
DB 
RCT 
PLC 
N=29; 
Fibromyalgia
Ketamine (0.3 
mg/kg) vs placebo 
(NS) over 30 
minutes over 2 
separate days 
[ketamine 
sensitivity 
detection]; ketamine 
vs placebo (NS) 
over 2 separate days 
with one week 
washout [ketamine 
effect] 
Decrease in VAS 
score during and 
up to 60 minutes 
after infusion; 
decrease in referred 
pain and temporal 
pain 
Not 
documented 
Leung 
(2001) 
DB 
RCT 
PLC 
N=12; Post 
nerve 
damage 
pain 
ketamine (IV 
infusion targeted to 
50, 100 and 150 
ng/ml) vs alfentanil 
(IV infusion 
targeted to 25, 50 
and 75 ng/ml) vs 
placebo 
(diphenhydrinate)
No reduction in 
spontaneous VAS 
pain scores; dose 
dependant 
decrease in 
stroking pain score.
1/3 of ketamine 
subjects 
reported light-
headedness, 3 
subjects sedated 
Mitchell 
(2002) 
DB 
PLC 
RCT 
N=35; 
Alloynia, 
hyperalgesi
a and 
hyperpathia 
secondary 
to critical 
limb 
ischemia 
Ketamine (0.6 
mg/m IV) with 
normal opioid doses 
vs placebo (NS) 
over 4 hours 
69% of patients 
reported BPI 
improvement 5 
days post 
administration 
6 patients "felt 
more emotional 
than usual" 
Gottrup 
(2006) 
DB 
RCT 
PLC 
N=19; 
Patients 
with nerve 
damage and 
allodynia 
Ketamine (0.1 
mg/kg IV bolus, 
then 0.007 
mg/kg/min 
infusion over 7 
minutes) vs 
lidocaine (5mg/kg 
IV) vs placebo (NS)
Reduction of 
spontaneous pain 
by VAS (mean 30% 
reduction), 
reduction of 
evoked pain to 
brush and pinprick 
by electronic VAS. 
No effect on 
allodynia. 
5 patients 
reported 
tiredness, 4 
dizziness, 4 
paresthesia,  3 
dry mouth, 1 
patient 
dropped from 
study for 
aggressive 
behaviour and 
hallucinations 
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Year 
Design
Patient 
population 
and 
numbers 
Design/ 
Methodology 
Outcomes 
Withdrawal/ 
Side Effects 
Schwartzm
an (2009) 
DB 
RCT 
PLC 
N=19; At 
least 6 mo of 
CRPS and 
failed three 
previous 
treatments
0.1 mg Clonidine 
and 2 mg of 
Midazolam then 
Ketamine (0.35 
mg/kg infusion 
over 4 hours; 50% 
first day 75% 
second day) vs 
placebo (NS) 
Statistically 
significant decrease 
in ‘pain in most 
affected area’, 
‘burning pain’ 
‘overall pain; and 
‘pain when lightly 
touched’ by pain 
questionnaire; 
ketamine group did 
not return to baseline 
level of pain
4 people in 
ketamine group 
reported 
nausea, 
headache, 
tiredness or 
dysphoria 
Mercadante 
(2000) 
DB 
RCT 
PLC 
N=10; 
Cancer 
patients on 
morphine 
therapy and 
Karnofsky 
score > 50 
Ketamine (0.25 
mg/kg) vs ketamine 
(0.5mg/kg) vs 
placebo (NS) 
infused over 30 
minutes x 1 each 
Significant 
decrease in pain 
intensity at both 
ketamine doses 3 
hours after 
administration on 
10 point scale; 
more pronounced 
with 0.5mg/kg dose
4 patients 
experienced 
hallucinations; 
2 patients 
experienced 
"out-of-body" 
sensation 
Jorum 
(2003) 
DB 
RCT 
PLC 
N=12; Post 
traumatic or 
herpetic 
neuralgia 
Ketamine (60 
mcg/kg over 5 min 
then 6 mcg/kg/min 
for 20 min) vs 
alfentanil  
(7 mcg/kg bolus 
then 0.6 
mcg/kg/min for 20 
min) vs placebo 
(NS) x 1 session 
each 
Decrease in VAS 
score to 
spontaneous pain 
and thermal 
hyperalgesia; no 
change on thermal 
cold threshold 
5 patients 
experienced 
fatigue,  
6 experienced 
dizziness,  
3 experienced 
"feeling of 
unreality", 8 
patients reported 
feeling 
intoxicated/ 
relaxed 
Oga (2002) 
SB 
RCT 
PLC 
N=10; 
Chronic 
neuropathic 
pain 
Placebo (5ml NS IV) 
x 2 then Ketamine (5 
mg IV q5min) x 3 
Average decrease 
on NRS pain scale 
from 10 to 3.75 
with ketamine 
treatment 
compared with no 
significant decrease 
in saline treatment
Overall 
significant 
increase in BRPS 
scale of negative 
symptoms 
(blunted affect, 
emotional 
withdrawal and 
motor 
retardation) 
Table 5. RCTs of IV Route 
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7. IV ketamine regimen 
In experimental ischemic pain, it was observed that there were consistent increases of pain 
thresholds for plasma concentrations of racemic ketamine more than 160 ng/mL (0.36 
µmol/L) (Clements, 1982). However, it has been difficult to establish clear dose-response 
relationship in clinical situations.  The solution used for anesthesia is also utilised to prepare 
appropriate solutions for parenteral infusions. When given as an infusion, it can be diluted 
with NS (normal saline 0.9%) in a 1:1 strength (100 mg ketamine in 100 ml NS), and infused 
via a infusor for accuracy. The administration of ketamine must happen on a fully 
monitored place with appropriate resuscitation equipments.  
As a general statement, parenteral administration, IV or SC, in the range 0.125–0.5 
mg/kg/hr, appears to be optimal (level II) but there are occasional reports of larger or 
smaller doses (Hocking, 2003). The titration is usually dictated by patient’s tolerability and 
clinical usefulness. Frequent (30 mins to 60 mins) assessments of pain and other measures of 
analgesia must be done. Once a reasonable upper level of infusion is established it may be 
given for 2-3 days. However there are no clear recommendations, but anecdotal reports 
suggest that a longer duration of treatment has more chance of effective analgesic actions 
which are prolonged and sustained. We have observed that the effects in some patients 
might last up to weeks to months.  
If intermittent dosing is planned, it may be wise to consider night-time dosing as it can 
reduce side effects (level IV), perhaps because of the fact that patients tend to be more 
relaxed or perhaps because sleep intervenes (Hocking, 2003). 
8. Conversion to oral ketamine (initiation and maintenance) 
In opioid naïve patients, the recommended starting dosage in ketamine naïve patients is 0.5 
mg/kg racemic ketamine or 0.25 mg/kg S-ketamine as a single oral dose. Doses can be 
increased in steps of 0.5 or 0.25 mg/kg according to the efficacy and adverse effects, 
respectively (Blonk, 2010).  
According to Soto et al (2011), oral ketamine seems to be most effective when used at an 
initial dose of 0.3 to 0.7 mg/kg per d, titrated up to every 6 hours. This is based on several 
case reports most of which have used an initial parenteral test. For use of oral ketamine at 
the end of life, data published suggests a starting dose of 30 to 150 mg/d titrated up to 60 to 
375 mg/d as the final dose.  
For patients who have been on parenteral ketamine, the dose conversion is not simple. 
Blonk suggests that the daily dosage can be kept equal and, depending on clinical effect 
and/or adverse effects, is slowly increased (Blonk 2010). This is mostly in contrast with 
others who recommend lower conversion rates. Fitzgibbon and others started with a lower 
dose which was approximately one-third of the parenteral ketamine dose (Fitzgibbon, 2002). 
Most agree that a conversion factor of 15% is appropriate (Soto, 2011). Convert from 
intravenous to oral route using at least 15% of the total parenteral dose in up to 4 divided 
doses (70-kg patient, intravenous ketamine infusion 0.1mg/kg per h ¼ oral ketamine 20 mg 
every 12 hours). After the intravenous infusion, reduce opiate by 25% daily, once adequate 
analgesia has been reached. Titrate up by 0.3 mg/kg daily until adequate analgesia is 
achieved or side effects occur. The number of divided doses necessary for continuous 
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analgesic effect can range from once daily up to a frequency of 6 times daily (Blonk 2010). 
The duration of effect after a single dose can range from a few hours to 24 h or more. 
9. Challenges and limitations of ketamine use in chronic pain 
1. Unavailability: the use of Ketamine for chronic pain is not approved and is off label. 
There are no commercially available preparations. The injection solution has been used, 
both for parenteral and oral use. Because of its higher potency, the S (+) racemate of 
ketamine is approved for use in Europe where it is commercially available as a 
preservative-free formulation for the treatment of pain by oral, parenteral, and 
neuroaxial administration (Ben Ari, 2007).  
2. Choosing the right patient, in terms of responsiveness. 
3. Choosing the right dose, duration and route of administration: There are no fixed 
strategies. Even if a patient is responsive to parenteral ketamine he may not be as 
responsive in the longer run (Hocking, 2003). For oral route, the dose conversion is not 
straight forward and not based solely on decreased bioavailability.  
4. There is no consistent dose–response relation. Even if one theoretically takes the serum 
levels of ketamine to maintain it at only a level required for therapeutic actions and not 
unwanted side effects, it is not possible to do so as the pharmacodynamics is still not 
entirely clear.  
5. Managing side effects; specific side effects related to subcutaneous and intranasal route 
have been mentioned above. The most frequently observed adverse effects were effects 
on the central nervous system, such as sedation, somnolence, dizziness, sensory 
illusions, hallucinations, nightmares, dissociative feeling and blurred vision. Most 
consider hallucinations as most disturbing (Blonk, 2010). Patients also mentioned 
gastrointestinal adverse effects, such as nausea, vomiting, anorexia and abdominal pain. 
It is also known to cystitis and other urinary complications when used on a longer 
duration and in addicts. 
6. Addiction: It is used as a street drug because of its psychotomimetic properties. It can 
be obtained as powder by heating the injection fluid, and used through snorting or 
inhaling (Blonk, 2010). 
7. Monitoring for long term effects and change: Long term effects are unknown. There 
have been only a few case reports which have followed the patients for months to years 
on ketamine treatment. The knowledge that NMDA receptors are associated with 
several other functions, it is prudent to assume that long term side effects are possible, 
and should be kept in mind. 
10. Long term use 
In neuropathic pain patients on long term treatment, Enarson (1999) used oral ketamine up 
to 100-240 mg per day in 14% patients who continued to use it for at least an year. Many 
others have used it on a long term basis (Furuhashi-Yonaha, 2002). Lack of evidence 
regarding efficacy, and the poor safety profile, do not support routine use of oral ketamine 
in chronic pain management. There is only one case series (N = 32) which specifically 
studied the side-effects of ketamine in the long-term treatment (3 months) of neuropathic 
pain (Cvrcek P, 2008). Literature is not conclusive about the differences in safety profiles of 
ketamine as racemic mixture and S-ketamine (Kohrs, 1998). 
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11. Conclusions 
Since there are no guidelines or good evidence regarding the introduction and use of 
ketamine in chronic pain conditions, the above based indications are mostly based on 
clinical reasoning, mostly with the view that NMDA receptors are involved in the 
generation or sustenance of the pain condition. Chronic pain conditions are quite 
heterogeneous in their pathophysiology; and there is still a huge knowledge gap in 
understanding several of them with regards to their clinical symptoms and variations. We 
also do not know how ketamine modulates pain pathways or its various actions leading to 
analgesic mechanisms. We still do not know whether oral route is better for analgesia. It has 
been suggested that oral ketamine administration causes fewer side effects (Hocking, 2003). 
Perhaps because of the smaller plasma levels an improved side effect profile of nor-
ketamine is observed. With the above considerations, we are left with exploring its analgesic 
potential for the benefit of patients who have resistant chronic pain condition, despite not so 
good evidence. Many to most patients do not respond; in fact according to some estimates 
only up to 30% respond (Hocking, 2003). Considering placebo responses come quite close to 
it in numbers, it is not certain if it’s a true response. Rabben and Oye suggested that there 
could be changes which may make the patient not susceptible to NMDA antagonists, as the 
clinical condition worsens. We might be able to improve the numbers of true responders if 
we get to know whether there are any variables, either disease specific or patient specific, 
telling us which patients may respond. In that direction there has to be further research and 
exploration. Until then it is not easy to formulate evidence based guidelines, despite having 
so many RCTs. From a present stand point use of ketamine is still directed by 
personal/clinician’s preference, availability of resources, patient’s acceptability, and above 
all a patient specific approach in terms of appropriate route, dose and duration. 
Part B: Lidocaine 
12. Pharmacological basis of Lidocaine use in neuropathic pain 
Lidocaine is a local anesthestic compound belonging to the amide group. The chemical 
structure of lidocaine is 2,6-xylidine coupled to diethylglycine by an amide bond. Lidocaine 
was first synthesized in 1943 and was used for many years as a local anesthetic agent. It is 
metabolized chiefly by the liver, and the major pathway of degradation involves conversion 
to monoethylglycylxylidide, to 2,6-xylidine and finally to 4-hydroxy-2,6-xylidine. These and 
various other metabolites are excreted in the urine. In addition, a small percentage of 
unchanged lidocaine, up to 10 percent, is also excreted in the urine.The major metabolic end 
product is 4-hydroxy-2,6-xylidine since up to 70 percent of an administered dose of 
lidocaine appears as this compound in the urine. The chemical structure of lidocaine is given 
as below. 
Lidocaine has been well studied and used as a local anesthetic agent. It was realised to have 
antiarrhythmic potential and has also been widely used for that purpose, as class IB agent. 
The first clinical use of lidocaine infusion in pain treatments was by 2 anesthesiologists 
(Bartlett and Hutaserani, 1961), for post-operative pain relief. Since then it has been used for 
various chronic pain syndromes, mostly of neuropathic nature, such as diabetic neuropathy, 
postherpetic neuralgia, and deafferentation pain. 
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Fig. 3. Lidocaine chemical structure 
How exactly systemic lidocaine works in neuropathic pain conditions and why it does work 
on only a selected number of patients is not yet completely known. However, the following 
description is based on the presently accepted concept (Mao & Chen, 2000). 
1. Lidocaine acts on sodium channel receptors which functions as the basic unit of nerve 
action potential generation. 
2. Neuropathic pain generates from ectopic, abnormal discharges of injured nerves in 
many neuropathic pain conditions (Nordin 1984). 
3. Lidocaine is supposed to have a differential action; suppresses the ectopic discharges 
but does not interfere in the normal neural discharges. 
Neuropathic pain is complex and heterogeneous. Apart from various diverse etiologies, it is 
also suggested that within diagnostic groups of neuropathic pain patients, there may be 
subgroups with distinct mechanisms and therefore possibly differing responses to drug 
treatments (Attal, 2004). Symptoms and signs of neuropathic pain may include spontaneous 
pain, hyperalgesia, allodynia, pain summation, and radiation of pain beyond the affected 
area (Dyke, 1984).There are many animal studies indicating that peripheral mechanisms of 
neuropathic pain may involve spontaneous ectopic discharges from the injured nerves. 
Experimentally, such injury may involve the form of complete deafferentation, loose nerve 
ligation, ligation of individual nerve root (Mao & Chen, 2000). When a peripheral nerve is 
injured the afferent input can be generated spontaneously without activation of peripheral 
receptors. Such input is referred to as spontaneous ectopic discharges (Devor, 1991). 
Electrophysiological studies have suggested that ectopic discharges can be initiated along 
the injured nerve, DRG, and peripheral neuromata (Wall and Gutnick, 1974; Mao & Chen, 
2000). Such ectopic discharges may last for a few hours to many days after nerve injury. It is 
possible to distinguish the origin of ectopic discharges as “neuromata- high frequency, 
rhythmic, spontaneous discharges” and “DRG neurons- slow, irregular activities in the 
absence of central or peripheral input”. Such aberrant, ectopic action potentials are 
supposed to be conducted along the nerve via the activation of sodium channels.  
13. Sodium channel and neuropathic pain 
The voltage-gated ion channels (VGICs) are a super family of glycoprotein molecules that 
form membrane spanning channels that ‘gate’ in response to changes in membrane 
potential. The biophysical properties include: channel opening or ‘activation’ which is 
dependent upon membrane potential, rapid ‘inactivation’ (which is governed not only by 
membrane potential but also time) and selective ion conductance. The major structural 
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component of the channel is a protein of approximately 260 kDa that has been named the 
alpha subunit. The alpha subunit comprises four repeated structural motifs (named I–IV) 
consisting of six alpha helical transmembrane spanning domains separated by intra and 
extracellular loops. These four repeated domains fold together to form a central pore and it 
is their structural components that determine selectivity and conductance of the ion (Scolz 
A, 2002). The central pore has been determined to be aqueous in nature as it has the capacity 
to conduct very large numbers of sodium ions through a single channel. By 
electrophysiology, biochemical purification and cloning, several different sodium channel a-
subunits, named as “NaV1.1–1.9” have been identified. Studies have shown a link between 
several Nav channels and pain, namely 1.3, 1.7, 1.8 and 1.9. Nav 1.3 mediates the compound 
tetrodotoxin (TTX), a poison from the puffer fish, and has faster activation and inactivation 
kinetics. It is highly expressed in sensory nerve tracts and spinal cord white matter, dorsal 
roots and deep laminae of the dorsal and ventral horn. This channel is supposed to be 
involved in the development of spontaneous ectopic discharges and sustained firing 
associated with the injured nerves. Nav 1.3 expression is seen to be increased 20-30 fold in 
neuropathic pain models. Nav 1.7 and Nav 1.9 are observed to be associated with 
inflammatory or nociceptive pain (Wood et al, 2004). Functionally the sodium channels exist 
in three possible conformational states and it is the transition between these states that 
allows selective and temporally regulated ionic conductance. When a stimulus provides a 
depolarizing change in the cellular membrane potential, the ion channels undergo a physical 
conformational change and the so-called ‘activation gate’ is opened. Activation is very 
rapid, occurring within a fraction of a millisecond and is due to movement of gating charges 
within the membrane electric field. When the activation gate is opened, the channel pore 
selectively conducts sodium ions down an electrochemical gradient from the extracellular 
space to the cell interior. Within a few milliseconds, the sustained depolarization results in 
termination of the sodium conductance by a process known as inactivation. This occurs very  
 
Fig. 4. Sodium channel kinetics as related to membrane potential  
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rapidly, producing attenuation of the sodium current and for this reason the process is often 
referred to as ‘fast’ inactivation. The second type of sodium channel inactivation, termed 
slow, occurs next. The ability of channels to recover from the fast inactivated state is 
dependent upon membrane potential and time, and is a mechanism that ensures adequate 
time for recovery before reopening of the channel. 
Local anesthetics, including lidocaine are charged at a PH below 6. The uncharged form is 
lipid soluble. It is now well understood and appreciated that LAs diffuse across the lipid 
membrane before getting to their active site. The receptor lies within the pore. The charged 
form of the compound acts on the receptor in a use dependent or phasic block. This means 
increasing impulses leads to accumulation of inhibition. The guarded hypothesis theory also 
means the binding site is within the pore and the pore has to be open for the LA molecule to 
bind. The impact of use dependent block would mean that as the firing frequency of the 
nerve fibre increases, lower concentrations of local anesthetics would be needed to block the 
action potentials (Scholz A, 2002).  
14. Lidocaine in neuropathic pain 
Lidocaine acts on these sodium channels to block the impulse transmission and selectively 
act on ectopic discharges (spontaneously produced without external stimuli). It is not clear, 
however, whether LAs acts by blocking impulse propagation or whether it prevents the 
very initiation of abnormal discharge. This should lead to the clinical inference that 
spontaneous pain symptoms must be more susceptible for lidocaine induced pain relief 
rather than evoked pain symptoms. In human studies on neuromata, two studies examined 
spontaneous discharges associated with peripheral nerve fibres following limb amputation. 
Spontaneous nerve activities recorded were not changed after local infiltration of neuromata 
with 1% lidocaine indicating a source of generators independent of neuromata. However, 
local lidocaine does block burst activities induced by tapping neuromata (Mao & Chen, 
2000). However this is not the case in many other studies. On further analysis, it is also 
proposed that allodynia may represent a central phenomenon which is secondarily activated 
because of the sensitization of sodium channels on Ab fibres. In this regard, a model of 
neuropathic pain has been proposed in which ongoing nociceptive afferent input from a 
peripheral locus is thought to maintain the dynamically-altered central process underlying 
allodynia (Mao & Chen, 2000).  
1. Acting peripherally, a number of studies have demonstrated that lidocaine suppresses 
ectopic activity arising out of injured neurons at clinically relevant doses. Another 
interesting observation is that systemic lidocaine has been shown to have dissociative 
effects on nerve conduction and ectopic discharges, i.e. suppression of ectopic 
discharges without blocking nerve conduction (Devor et al, 1992), indicating that 
sodium channels generating ectopic discharges are likely to be different from those 
mediating normal action potential conduction along a peripheral nerve.  
2. At the level of spinal cord, lidocaine is also known to induce a selective depression of 
C fibre-evoked activity among spinal cord-wide dynamic range neurons and decrease 
the hyperexcitability of dorsal horn neurons in neuropathic pain models (Woolf, 1985). 
3. Supraspinal mechanisms of lidocaine actions are demonstrated by its effectiveness in 
hemispheric lesions and central pain (Attal et al, 2000). Lidocaine can also induce 
changes in neuropathic pain behaviours (Mao & Chen, 2000). Neuropathic pain 
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behaviours responding to systemic lidocaine include hyperalgesia and allodynia. 
Procaine infusions on healthy volunteers have shown selective activation of anterior 
amygdalocentric limbic system. Lidocaine infusions can give rise to acute psychiatric 
reactions especially in patients having significant affective component (Leong & 
Solason, 2000).  
15. Lidocaine use in clinical practice 
Clinically the response to lidocaine varies in different chronic pain syndromes. In general 
peripheral neuropathic conditions are more susceptible (Galer et al, 1993; Tremont-Lukats  
et al, 2005; Attal et al, 2000). Even with the same condition the responsiveness may differ 
between two individuals with similar history and symptoms. Further even in a single 
patient only a subset of neuropathic pain symptoms (modality specific) may be responsive. 
Using quantitative sensory tests, Attal et al have shown that IV lidocaine induced selective 
and differential analgesic effects in patients with central neuropathic pain (Attal et al, 2000). 
Ketamine alleviated spontaneous pain and mechanical allodynia/hyperalgesia, but had no 
effect on thermal allodynia/hyperalgesia. Wallace et al studied the effects of IV lidocaine in 
CRPS patients and used diphenhydramine as a control. Intravenous lidocaine and 
diphenhydramine had no significant effect on the cool, warm, or cold pain thresholds. The 
effect on allodynia was seen only at the maximum plasma range. Lidocaine affected pain in 
response to cool stimuli more than mechanical pain in subjects with neuropathic pain 
(Wallace et al, 2000). This is in contrast to the study by Attal et al.  Hence it is still not certain 
which modalities of neuropathic pain are particularly sensitive to lidocaine infusions.  
Previously lidocaine was given as IV boluses; presently it is mostly given as an infusion. In 
many centres it is given using a computer controlled, targeted infusions. The commonly 
used range is 3-5mg/kg over 30-60 minutes. This may or may not involve an initial bolus. 
Most studies have shown to achieve a plasma concentration of 2-5 µg/ml (Mao & Chen, 
2000). Ferrante et al studied the dose response and plasma concentration in 13 patients. 
Lidocaine was given at a rate of 8.35 mg/min (500 mg). Ten patients had complete pain relief 
as measured by VAS scores and scores from the short form of the McGill Pain Questionnaire 
and the Multidimensional Pain Inventory. After a certain plasma level of 0.62 µg/ml, there 
were steep changes of pain scores with small changes in lidocaine plasma concentration 
(Ferrante 1996). Carroll et al employed an appropriate dose to produce plasma levels of 5 
µg/ml (Carroll 2007). Indeed up to  15 µg/ml was achieved in some initial studies without 
serious sequelae (Schinder, 1996; Carroll, 2007). Not much knowledge is available regarding 
the duration of pain relief after an IV bolus versus continuous infusion of lidocaine. The onset 
of lidocaine effect on pain relief ranges from 1 to 45 min after lidocaine administration (Mao & 
Chen, 2000; Carroll, 2007). There is still no consensus about the appropriate duration of 
observation after either lidocaine bolus or infusion. Apart from the anecdotal reports there are 
no studies documenting longer lasting pain relief (days-months).  
16. Review of literature 
The use of lidocaine in clinical practice has been well reviewed earlier by Tremont-Lukats et 
al (Tremont-Lukats et al, 2005). Their systematic search revealed 13 trials using lidocaine 
infusion. Most of these studies have fewer subjects and tend to suffer from the fallacy of 
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Study Design 
Patient 
Population
Treatment Outcomes 
Adverse/Side 
Effects 
Gottrup 
(2006) 
DB RCT 
PLC 
N=19, 
Patients 
with nerve 
damage 
and 
allodynia 
Ketamine (0.1 
mg/kg IV bolus, 
then 0.007 
mg/kg/min 
infusion over 7 
minutes) vs 
lidocaine 
(5mg/kg IV over 
30 min) vs 
placebo (NS) 
Both ketamine and 
lidocaine 
significantly reduced 
evoked pain to 
pinprick stimuli; 
ketamine was 
superior to lidocaine 
in reducing 
spontaneous pain 
7 tiredness, 4 
nausea, 3 
paresthesia, 3 
blurred vision, 
3 changed 
taste, 3 
dysarthria, 2 
headache, 2 
dry mouth 
Viola 
(2006) 
DB RCT 
PLC 
N=15, 
diabetic 
neuropath
y, previous 
responders 
to lidocaine
Lidocaine 
(5mg/ml IV) vs 
Lidocaine 
(7.5mg/ml IV) vs 
placebo (NS), 
5ml/kg over 4 
hours x 1 each, 
four week 
washout 
Both doses of 
lidocaine decreased 
MPQ resting pain 
scores compared to 
placebo; effect lasted 
up to 28 days post-
infusion 
1 patient 
reported light-
headedness 
with 7.5 
mg/ml 
infusion 
Finnerup 
(2005) 
DB RCT 
PLC 
N=24, 
spinal cord 
injury with 
neuralgia 
at or below 
level of 
injury 
Lidocaine 
(5mg/kg IV) vs 
placebo (NS) over 
30 min x 1 
Significant reduction 
of spontaneous pain 
in treatment group; 
no effect on evoked 
pain 
11 somnolence, 
7 dizziness, 7 
dysarthria, 7 
lightheaded, 3 
blurred vision 
Attal 
(2004) 
DB RCT 
PLC 
N=22, 
post-
herpatic or 
post-
traumatic 
neuralgia  
Lidocaine 
(5mg/kg IV) vs 
placebo (NS) over 
30 min x1 
Significant reduction 
of spontaneous pain 
by VAS, as well as 
mechanical 
allodynia; no effect 
on thermal or 
hyperalgesia 
16 patients 
experienced 
side effects 
including 
somnolence, 
lightheadednes
s, periorbital 
numbness 
Medrik-
Goldberg 
(1999) 
DB RCT 
PLC 
N=30, 
Sciatica 
Lidocaine 
(5mg/kg IV) vs 
amantadine 
(2.5mg/kg IV) vs 
placebo (NS) over 
2 hours x 1 
Lidocaine 
significantly reduced 
spontaneous pain on 
VAS scale up to 30 
min after infusion as 
compared with 
amantadine and 
placebo; also 
significant decrease 
in SLR evoked pain 
compared to other 
two arms
None reported 
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Study Design 
Patient 
Population
Treatment Outcomes 
Adverse/Side 
Effects 
Scrivani 
(1999) 
SB RCT 
PLC 
N=30, 
Chronic 
neurogenic 
facial pain 
Lidocaine (100mg 
IV) vs 
Phentolamine 
(30mg IV) vs 
placebo (NS) 
infused over 5-10 
min x 1 
Lidocaine infusion 
decreased 
spontaneous pain in 
16 patient on 10 
point VAS for up to 
30 min 
None reported 
Baranowsky
(1999) 
DB RCT 
PLC 
N=24, 
post-
herpatic 
neuralgia 
Lidocaine (0.5 
mg/kg/h IV) vs 
Lidocaine 
(2.5mg/kg/h IV) 
vs placebo (NS) 
over 2 hours x 1 
No significant 
difference in 
spontaneous pain on 
MCQ and VAS pain 
scales, allodynia and 
pressure provoked 
pain were both 
significantly 
improved with 
either dose of 
lidocaine 
Not reported 
Galer 
(1996) 
DB RCT 
N=9, 
Peripheral 
neuropathic
pain 
Lidocaine 
(2mg/kg IV) vs 
Lidocaine (5 
mg/kg IV) over 
45 min x 1 
Both arms had 
significant decrease 
in VAS resting pain 
scores; higher dose 
lidocaine produced 
significantly  
greater pain  
relief than lower 
dose 
1 patient 
dropped out 
due to severe 
dizziness and 
tinnitus 
Wallace 
(1996) 
DB RCT 
PLC 
N=11, 
post-
traumatic 
neuropathic
pain 
Lidocaine 
(targeted plasma 
concentrations of 
0.5, 1, 1.5, 2 and 
2.5 mcg/ml 
sustained over 10 
min) vs placebo 
(NS) x 1 each  
Significant decrease 
in spontaneous VAS 
pain scores starting 
at 1.5mcg/ml 
concentration; no 
change in evoked 
pain 
6 patients 
reported 
lightheadednes
s, 1 patient 
reported 
nausea 
Bruera 
(1992) 
DB RCT 
PLC 
N=?, 
Neuropathic
cancer pain
Lidocaine 
(5mg/kg IV) vs 
Placebo (NS) over 
30 min x 1 
No change in VAS 
pain scores between 
groups 
Unknown 
Rowbotham 
(1991) 
DB RCT 
PLC 
N=19, 
Post-
herpetic 
neuralgia 
Lidocaine (?IV) vs 
Morphine (?IV) vs 
Placebo (NS) 
Both morphine and 
lidocaine reduced 
pain intensity 
Unknown 
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Study Design 
Patient 
Population
Treatment Outcomes 
Adverse/Side 
Effects 
Wallace 
(2000) 
DB RCT 
PLC 
N=16, 
CRPS 1 
and 2 
Lidocaine 
(1,2,3mcg/ml 
plasma IV) vs 
placebo 
(diphenhydramine)
x 1 
Significant decrease 
in spontaneous VAS 
pain scores in 
3mcg/ml; all 
concentrations 
caused significant 
decrease in response 
to stroking and cool 
stimuli in the 
affected area
Average side 
effect score 
(out of 100) for 
light 
headedness 
and sedation 
was more 
significant 
than placebo 
Ellemann 
(1989) 
DB RCT 
PLC 
N=10, Cancer 
patients 
with 
cutaneous 
allodynia
Lidocaine 
(5mg/kg IV) vs 
placebo (NS)  x 1 
2 patients reported 
subjective pain relief 
in treatment arm, 3 
in placebo arm 
Unknown 
Sharma 
(2009) 
DB RCT 
PLC 
N=50, 
cancer 
patients 
with 
opioid 
refractory 
pain 
Lidocaine 
(2mg/kg bolus 
over 20 minutes 
followed by 
2mg/kg infusion 
over 2 hr) vs 
placebo (NS) 
Significant decrease 
in 10 point numeric 
pain scores in 
treatment group 
after 2 hours; 
significantly longer 
duration of analgesia 
than placebo
7 patients with 
periorbital 
numbness, 8 
with tinnitus 
Kastrup 
(1987) 
DB RCT 
PLC 
N=?, 
Diabetic 
neuropathy 
of >6 
months 
Lidocaine 
(5mg/kg IV) vs 
placebo (NS) 
Significant beneficial 
effect of lidocaine 
arm on pain 
symptoms 1 and 8 
days post infusion 
Unknown 
Tremonts-
Lukats 
(2006) 
DB RCT 
PLC 
N=32, 
Peripheral 
neuropathic 
pain  
Lidocaine (1,3,5 
mg/kg IV) vs 
placebo (NS) over 
6 hours x 1 each 
Significant change in 
percentage pain 
intensity difference 
between 5mg/kg 
arm and placebo up 
to four hours post-
infusion
10 light-
headedness, 4 
nausea, 6 
periorbial 
numbness, 6 
headache, 3 
incoordination 
Gormsen 
(2009) 
DB RCT 
PLC 
N=13, 
chronic 
neuropathic
pain 
Lidocaine 
(5mg/kg IV) vs 
NS1209 (AMPA 
receptor 
antagonist 322 mg 
total) vs placebo 
(NS) over 4 hours 
x1 
No difference in any 
treatment arms of 
spontaneous current 
pain, both NS1209 
and lidocaine 
exhibited significant 
effects on resting 
pain compared to 
placebo 
All lidocaine 
patients 
experienced 
adverse events 
including 
headache, 
dizziness, 
somnolence, 
fatigue, 
cognitive 
impairment 
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Study Design 
Patient 
Population
Treatment Outcomes 
Adverse/Side 
Effects 
Attal (2000) 
DB RCT 
PLC 
N=16, post 
stroke or 
spinal cord 
injury pain
Lidocaine 
(5mg/kg IV) vs 
placebo (NS) over 
30 min x 1 
Significant reduction 
in spontaneous pain 
on VAS in treatment 
arm; no significant 
difference in 
mechanical or 
thermal stimulation 
thresholds
7 patients with 
light-
headedness, 5 
somnolence, 3 
nausea/ 
vomiting, 3 
dysarthria, 2 
malaise 
Marchettni 
(1992) 
RCT PLC 
N=10, 
organic 
nerve injury 
causing 
neuropathic 
pain
Lidocaine 
(unknown IV) vs 
Placebo (NS) 
Subjective report of 
mechanical 
hyperalgesia and 
spontaneous pain 
decreased significantly 
in treatment arm
Unknown 
Wu (2002) 
DB PLC 
RCT 
N=32, 
phantom 
limb or 
stump pain
Lidocaine 
(1mg/kg bolus 
then 4mg/kg IV) 
vs Morphine 
(0.05mg/kg bolus 
then 0.2mg/kg IV) 
vs placebo 
(Diphenhydramin
e 10mg bolus then 
40 mg IV) over 40 
min x 1
Lidocaine 
significantly 
decreased stump 
pain by VAS pain 
score, Morphine 
decreased both 
stump and phantom 
limb pain.  
No difference 
in sedation 
scores between 
treatment arms 
Kvarnstro
m (2003) 
12 PT DB 
RCT PLC 
Long 
lasting, 
post-
traumatic 
neuropathic 
pain 
Ketamine (0.4 
mg/kg IV) vs 
Lidocaine (2.5 
mg/kg) vs placebo 
(NS) infused over 
40 minutes  
No significant 
difference in VAS 
resting score between 
lidocaine and placebo; 
no significant 
difference in any 
evoked VAS scores
9 somnolence, 5 
light-headedness, 
4 "out of body 
sensation", 3 
nausea, 2 pruritis, 
2 paresthesia 
Kvarnstron 
(2004) 
10 PT DB 
RCT PLC 
Spinal Cord 
Injury with 
Pain Below 
Injury Level
Ketamine (0.4 
mg/kg IV) vs 
Lidocaine (2.5 
mg/kg IV) vs 
Placebo (NS) over 
40 min 
No significant 
difference in response 
between lidocaine and 
placebo in VAS 
spontaneous pain 
scores and evoked 
allodynia 
5 somnolence, 1 
dizziness, 2 out 
of body 
sensation, 1 
change in 
hearing, 2 
paresthesias 
Lemming 
(2005) 
33 PT DB 
RCT PLC 
Patients 
with 
whiplash 
disorder 
Ketamine (0.3 
mg/kg infused 
over 30 min) vs 
Lidocaine vs 
morphine vs 
placebo (NS) 
No significant 
difference in 
response between all 
treatment arms; all 
treatment arms did 
illicit partial response
Not 
Documented 
Table 6. RCTs of IV Lidocaine use 
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heterogeneity with respect to disease treated, dose employed and outcomes measured. 
Despite the deficiencies, they were able to synthesise the data and do a meta-analysis. For 
the lidocaine trials considered for analysis, the median Jadad score was 3. In the lidocaine 
trials included for meta-analysis 165 patients received lidocaine and 164 patients were 
treated with placebo. Lidocaine was superior to placebo (Weighted Mean Difference -10.02 
mm; 95% CI: -16.51 to -3.54 mm, P > 0.002). The study concluded that systemic 
administration of sodium channel blocking drugs can relieve pain in selected patients with 
neuropathic pain and that this effect is superior to placebo. However, the mean effect was 
small (approximately 11 mm point on a 100 point scale). The commonly used dose range of 
lidocaine was 5mg/kg over 30-60 mins. The therapeutic benefit was seen more consistently 
with peripheral pain-trauma, diabetes and central pain. The duration of pain relief observed 
with lidocaine infusions are mostly short lived (up to 24 hrs). The same conclusion was 
drawn in the meta-analysis. Some animal experiments and few human trials have 
demonstrated prolonged effects far beyond the beyond the pharmacological half-time of 
lidocaine (Mao & Chen, 2000; Chaplan et al, 1995; Sinnott et al, 1999). The mechanism 
behind this is unknown.  
Another important drawback of most studies was the outcome measures considered; 
allodynia which is an evoked pain measure rather than spontaneous pain was evaluated. 
This study has also been criticized as the conclusions may not be clinically relevant, 
however good methodology has been employed. Because of the quality of the studies the 
calculation of side effects was significantly affected resulting in inappropriate conclusions 
(Rathmell & Ballantyne, 2005). Our search identified 23 studies and was further cross 
referenced with the studies in the systematic review. The table gives a complete list of 
studies including methodology, results and complications. The place of IV lidocaine 
infusion in treating neuropathic pain patients is difficult to establish. In clinical practice it 
may be looked as an additional tool for diagnosis and therapeutic management, mostly to be 
used in resistant or challenging neuropathic pain conditions when other treatments fail. It 
could also be used to provide relief in “acute on chronic pain” conditions. Some use an 
algorithm in which an IV therapeutic drug is utilised only after testing the patient with 1-2 
placebo treatments. But most employ a lidocaine test (see below), where in the patient is 
tested for responsiveness with increasing doses of lidocaine.  
17. Intravenous lidocaine test 
This is a test done to observe for pain relief achieved with IV lidocaine infusion. This is 
called a test only, because it is the first time that a particular patient having a specific 
neuropathic pain is being exposed to this treatment. Unlike a known analgesic such as 
opioid, lidocaine may not be effective or may cause significant dose related side effects even 
at minimal therapeutic range, which would limit its role in further management of pain 
condition. Since the effects are immediate and do not take time, one can quickly establish the 
clinical usefulness in a particular patient. 
This is done in an appropriately monitored setting including heart rate, ECG, blood pressure 
and pulse oximetry. In fact, there are no strict or established protocols. These variations 
make the usefulness of this test individual specific and generalisations cannot be made. The 
dose range of systemic lidocaine in the test varies extensively among pain centers, from 100 
mg/patient to 5 mg/kg of a patient's body weight (Mao & Chen 2000). The rate of 
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administration also varies from an IV push to a slow infusion over 30-60 min. Similarly the 
outcome measures of the lidocaine test also differ among pain centers: (1) what to measure to 
determine a positive test result, (2) how much change to be expected to indicate a positive 
result, and (3) when to measure after the lidocaine test to determine the test results. Some 
centres do blinding as reported earlier, however the blinding itself can be questioned as there 
are no active placebo controls. It is practically impossible for a patient not to notice CNS side-
effects after systemic lidocaine administration. Wallace et al used diphenhydramine as a 
placebo in their study (Wallace et al, 2000). This is perhaps appropriate considering its side 
effect as a sedative and causing light headedness, similar to lidocaine. 
18. Lidocaine test for the diagnosis of neuropathic pain syndromes 
Perhaps the lidocaine test has more value as a diagnostic tool to identify true neuropathic 
pain patients rather than a prognosticator for further lidocaine treatment. Marchettini 
performed this test on ten patients with organic nerve injury causing chronic neuropathic 
pain.  The effect of intravenous lidocaine versus saline was tested using psychophysical 
somatosensory variables. The variables assessed were the subjective magnitude of pain, area 
of mechanical hyperalgesia and presence and magnitude of thermal heat/cold hyperalgesia. 
Lidocaine was given in a dose of 1.5mg/kg over 60 secs and placebo-saline in the other 
group. The patients were then tested at 5, 15 and 35 mins intervals. It was found that 
spontaneous pain and mechanical hyperalgesia were consistently improved, transiently, by 
intravenous administration of lidocaine in all 10 patients; areas of hyperalgesia which 
extended beyond the territory of the nerve also improved transiently (Marchettini et al, 
1991). Carroll et al performed a non randomised cohort study on 71 patients with 
neuropathic pain with an objective to identify a subgroup of patients who are more 
responsive to IV lidocaine treatment by analysing differing pain qualities of neuropathic 
pain such as stabbing and heavy. Baseline heavy pain quality, but not stabbing quality 
predicted subsequent relief of pain intensity in response to lidocaine (Carroll, 2010). The 
predictive value of the lidocaine test for a positive oral trial of lidocaine congeners remains 
to be determined (Mao & Chen, 2000).  
19. Side effects and limitations 
The side effects are usually mild, dose-dependent, and always resolve with a decrease in the 
infusion rate or discontinuation of the drug. Tremor is a probably the first sign of toxicity. 
Other neurologic side effects include insomnia or drowsiness, light-headedness, dysarthria 
and slurred speech, ataxia, depression, agitation, change in sensorium, a change in 
personality, nystagmus, hallucinations, memory impairment, and emotional lability. 
Susceptibility increases in older adults or in those with heart failure, settings in which CNS 
levels are increased due to a reduced volume of distribution, and in patients with significant 
liver impairment in whom the metabolism of lidocaine is reduced. Seizures occur at a higher 
plasma level, but can occur at a lower concentration if lidocaine is given to patients 
receiving oral tocainide or mexiletine, which are congeners of lidocaine. Cardiac side effects 
are usually infrequent. The primary cardiovascular side effects include sinus slowing, 
asystole, hypotension, and shock. These problems are most often associated with overdosing 
or with the overly rapid administration of lidocaine. The elderly and those with significant 
pre-existing heart disease are at greatest risk. 
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There are several limitations and caveats with the use of IV lidocaine in chronic pain.  
1. As a sodium channel blocker it is expected that it relieves pain which is mostly 
spontaneous in origin, but most studies show that is effects more on evoked pain. 
2. There is known consistent results even when used with a similar condition on a 
different patient. 
3. There seems to be a subgroup of patients who truly respond to IV lidocaine therapy. 
The challenge is to identify them. 
4. Even in patients in whom it works, the duration of analgesia is short lasting (mostly 
hours). 
5. This also needs resources to administer, monitor treatment. 
6. Most of the orally available sodium channel blockers do not have the same results when 
used on patients responsive to lidocaine. 
20. Conclusion 
Lidocaine therapy is a promising therapy for patients with neuropathic pain. Its routine use 
cannot be still advised considering the evidence and limitations. However for a resistant and 
challenging neuropathic pain patient this option should be tried, at least to test the 
responsiveness and may be utilised on acute on chronic pain situations. Potentially it may 
also serve to identify true neuropathic pain responders from placebo responders.  
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